Literature DB >> 6937706

Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells.

A Floridi, M G Paggi, M L Marcante, B Silvestrini, A Caputo, C De Martino.   

Abstract

The action of Lonidamine [1-(2,4-chlorobenzyl)-1H-indazol-3-carboxylic acid] on respiration and aerobic lactate production of several murine tumor cells and normal differentiated murine cells was investigated. Lonidamine reduced the oxygen consumption in both normal and neoplastic cells. In contrast, it increased the aerobic glycolysis of normal cells but inhibited that of tumor cells. This selective action might be ascribed to the inhibition of mitochondrially bound hexokinase, which is usually absent in normal differentiated cells.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6937706

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  49 in total

Review 1.  Role of monocarboxylate transporters in human cancers: state of the art.

Authors:  Céline Pinheiro; Adhemar Longatto-Filho; João Azevedo-Silva; Margarida Casal; Fernando C Schmitt; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-02       Impact factor: 2.945

Review 2.  Adjudin--A Male Contraceptive with Other Biological Activities.

Authors:  Yan-Ho Cheng; Weiliang Xia; Elissa W P Wong; Qian R Xie; Jiaxiang Shao; Tengyuan Liu; Yizhou Quan; Tingting Zhang; Xiao Yang; Keyi Geng; Bruno Silvestrini; Chuen-Yan Cheng
Journal:  Recent Pat Endocr Metab Immune Drug Discov       Date:  2015

Review 3.  Interaction of oligomeric breast cancer resistant protein (BCRP) with adjudin: a male contraceptive with anti-cancer activity.

Authors:  Yan Ho Cheng; Pranitha Jenardhanan; Premendu P Mathur; Xiaojing Qian; Weiliang Xia; Bruno Silvestrini; Chuen Yan Cheng
Journal:  Curr Mol Pharmacol       Date:  2014       Impact factor: 3.339

Review 4.  Small mitochondria-targeting molecules as anti-cancer agents.

Authors:  Feng Wang; Marcia A Ogasawara; Peng Huang
Journal:  Mol Aspects Med       Date:  2009-12-06

5.  Modulation of antitumor alkylating agents by novobiocin, topotecan, and lonidamine.

Authors:  G N Schwartz; B A Teicher; J P Eder; T Korbut; S A Holden; G Ara; T S Herman
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 6.  Mitochondrial metabolism inhibitors for cancer therapy.

Authors:  Emma E Ramsay; Philip J Hogg; Pierre J Dilda
Journal:  Pharm Res       Date:  2011-09-15       Impact factor: 4.200

Review 7.  The Warburg effect revisited--lesson from the Sertoli cell.

Authors:  Pedro F Oliveira; Ana D Martins; Ana C Moreira; C Yan Cheng; Marco G Alves
Journal:  Med Res Rev       Date:  2014-07-12       Impact factor: 12.944

8.  The potential role of lonidamine (LND) in the treatment of malignant glioma. Phase II study.

Authors:  C M Carapella; M G Paggi; F Cattani; G B Ciottoli; A Floridi; B Iandolo; L Raus; A Riccio; A Caputo
Journal:  J Neurooncol       Date:  1989-05       Impact factor: 4.130

Review 9.  Mechanism of antineoplastic activity of lonidamine.

Authors:  Kavindra Nath; Lili Guo; Bethany Nancolas; David S Nelson; Alexander A Shestov; Seung-Cheol Lee; Jeffrey Roman; Rong Zhou; Dennis B Leeper; Andrew P Halestrap; Ian A Blair; Jerry D Glickson
Journal:  Biochim Biophys Acta       Date:  2016-08-04

10.  Fluosol-DA/carbogen with lonidamine or pentoxifylline as modulators of alkylating agents in the FSaIIC fibrosarcoma.

Authors:  B A Teicher; T S Herman; J Tanaka; B Dezube; A Pardee; E Frei
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.